Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2

Status

Recruiting 3Active not recruiting 2

Sponsor Class

INDUSTRY 67OTHER 66NIH 25NETWORK 5

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 5

Conditions

Carcinoma, Non-Small-Cell Lung 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Multiple Myeloma 5Breast Neoplasms 5Wilms Tumor 4Prostatic Neoplasms 4Neoplasms 4Hematologic Neoplasms 4Burkitt Lymphoma 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Plasmablastic Lymphoma 3Pancreatic Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma 3HIV Infections 3Ependymoma 3Colorectal Neoplasms 3Astrocytoma 3Recurrence 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Melanoma 2Medulloblastoma 2Lymphoma, T-Cell 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Kidney Neoplasms 2Hodgkin Disease 2Head and Neck Neoplasms 2

Interventions

Lenalidomide 3Dexamethasone 3Bortezomib 3daratumumab 2Calcium Dobesilate 2dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Injections 1Drugs, Generic 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
NETWORK × Multiple Myeloma × 30 days × Clear all
NCT06171685 2026-06-05

MMRC Horizon One: RRMM (MMRC-099)

Multiple Myeloma Research Consortium

Phase 2 Active not recruiting
300 enrolled
Plasma cell

Multiple Myeloma

NCT05243797 2026-06-04

MajesTEC-4

European Myeloma Network B.V.

Phase 3 Recruiting
1,594 enrolled
Plasma cell

Multiple Myeloma

NCT06918002 2026-06-01

ElLen

Intergroupe Francophone du Myelome

Phase 3 Recruiting
824 enrolled
Plasma cell

Multiple Myeloma

NCT04566328 2026-05-15

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Eastern Cooperative Oncology Group

Phase 3 Recruiting
1,450 enrolled
Plasma cell

Multiple Myeloma

NCT07085728 2026-05-15

Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
74 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡